Physician profile
Alan Alex
NPI 1033757695
$5,181.56
in general payments reported to CMS, 2019-2025
36 companies · $3,335 in 2025
The $3,335 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.25 · 2023: $42.78 · 2024: $1,782 · 2025: $3,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,608 · Education: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,608.34 |
| Education | $550.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,265.90 | 2024-2025 | Erleada, Akeega, Tecvayli |
| Janssen Scientific Affairs, LLC | $502.39 | 2024-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $445.75 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $244.00 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $220.43 | 2024-2025 | Adstiladrin |
| Astellas Pharma US INC | $206.66 | 2024-2025 | Xtandi |
| Incyte Corporation | $183.21 | 2024-2025 | Monjuvi, Jakafi, Niktimvo |
| Tolmar, INC. | $169.91 | 2024-2025 | Jatenzo, Eligard |
| Teleflex LLC | $162.38 | 2024 | Urolift |
| Novartis Pharmaceuticals Corporation | $156.72 | 2024-2025 | |
| Progenics Pharmaceuticals, INC. | $155.45 | 2024-2025 | Pylarify |
| Merck Sharp & Dohme LLC | $144.21 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Telix Pharmaceuticals | $143.47 | 2024-2025 | Illuccix |
| Pfizer INC. | $131.41 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $111.73 | 2025 | Enhertu, Tagrisso, Lynparza |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $101.20 | 2022-2024 | |
| Daiichi Sankyo INC. | $97.25 | 2025 | Enhertu, Datroway |
| Tempus Ai, INC | $94.45 | 2024-2025 | Xt Cdx |
| Sumitomo Pharma America, INC. | $73.13 | 2024-2025 | Gemtesa, Orgovyx |
| Bioprotect Medical, INC. | $65.19 | 2025 | Bioprotect Balloon Implant System |
| Genmab U.S., INC. | $51.39 | 2025 | Epkinly |
| Medtronic, INC. | $51.04 | 2025 | Interstim |
| Urogen Pharma, INC. | $50.68 | 2025 | |
| Olympus America INC. | $46.00 | 2025 | Itind System |
| Glaxosmithkline, LLC. | $42.78 | 2023 | Nucala, Trelegy Ellipta |
| Abbvie INC. | $39.52 | 2024-2025 | |
| 180 Medical, INC. | $29.84 | 2024 | Gentlecath |
| Eisai INC. | $26.99 | 2025 | |
| Kyowa Kirin, INC. | $25.87 | 2025 | |
| Avyxa Pharma, LLC | $23.84 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.62 | 2025 | Erleada |
| Recordati_rare_diseases_inc. | $22.65 | 2025 | Sylvant |
| Regeneron Healthcare Solutions, INC. | $21.24 | 2025 | Libtayo |
| Pharmacosmos Therapeutics INC. | $19.42 | 2025 | Monoferric |
| Novocure INC. | $17.22 | 2025 | Optune Lua (Novottf-200t) |
| Tersera Therapeutics LLC | $14.62 | 2025 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Alex listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.